van der Werf-Messing B, Menon R S, Hop W C
Int J Radiat Oncol Biol Phys. 1983 Apr;9(4):481-5. doi: 10.1016/0360-3016(83)90064-0.
Three-hundred-twenty-eight patients with bladder cancer category T2NxMo and 63 patients with category T3NxMo have been treated by 3 times 3.5 Gy external irradiation followed by a radium implant. Overall 5- and 10-year survival in the T2 category are 56%. In the T3 category they are 39% and 13%, respectively. The intercurrent death (i.e. without evidence of bladder malignancy) corrected actuarial survival percentage in the T2 category is 75% at 5 years and 69% at 10 years. The corresponding percentages in the T3 category are 62% and 59%. Prognosis is worsened by the following factors: more than 1 diagnostic transurethral resection, a pathological intravenous pyelography, non-papillary structure and poor degree of differentiation of the growth. Prognosis in category T3, as compared with category T2, is worse because of the prevalence of bad prognosticators in this T3 category. Therapeutic adaptation to these findings might improve prognosis in the future.
328例T2NxMo期膀胱癌患者和63例T3NxMo期膀胱癌患者接受了3次3.5 Gy的外照射，随后进行镭植入治疗。T2期患者的总体5年和10年生存率为56%。T3期患者的5年和10年生存率分别为39%和13%。T2期患者并发死亡（即无膀胱恶性肿瘤证据）校正后的精算生存率在5年时为75%，在10年时为69%。T3期的相应百分比分别为62%和59%。以下因素会使预后恶化：超过1次诊断性经尿道切除术、病理性静脉肾盂造影、非乳头状结构以及肿瘤分化程度差。与T2期相比，T3期的预后更差，因为该T3期不良预后因素更为普遍。根据这些发现进行治疗调整可能会改善未来的预后。
